Henry Schein (NASDAQ:HSIC) Given New $75.00 Price Target at Wells Fargo & Company

Henry Schein (NASDAQ:HSIC - Get Free Report) had its price objective dropped by investment analysts at Wells Fargo & Company from $80.00 to $75.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Wells Fargo & Company's price target indicates a potential upside of 8.60% from the company's current price.

A number of other brokerages have also commented on HSIC. Barrington Research decreased their price target on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a research note on Tuesday. StockNews.com downgraded Henry Schein from a "buy" rating to a "hold" rating in a report on Thursday, April 17th. Bank of America raised Henry Schein from an "underperform" rating to a "buy" rating and increased their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. UBS Group reduced their target price on Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a report on Wednesday, February 26th. Finally, Jefferies Financial Group boosted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a research report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $79.30.

Henry Schein Stock Up 0.2 %

Shares of HSIC stock traded up $0.17 on Tuesday, hitting $69.06. 65,995 shares of the stock were exchanged, compared to its average volume of 1,624,192. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average of $67.62 and a 200 day moving average of $71.46. The firm has a market capitalization of $8.46 billion, a P/E ratio of 28.42, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. The company had revenue of $3.17 billion for the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business's revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.10 EPS. Equities analysts anticipate that Henry Schein will post 4.74 EPS for the current year.

Insider Activity at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.08% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC boosted its stake in shares of Henry Schein by 23.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after purchasing an additional 143 shares during the period. Guggenheim Capital LLC raised its stake in shares of Henry Schein by 2.5% during the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock valued at $445,000 after acquiring an additional 159 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after purchasing an additional 169 shares during the period. Metis Global Partners LLC lifted its holdings in Henry Schein by 4.7% in the 4th quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock worth $291,000 after buying an additional 187 shares during the period. Finally, UMB Bank n.a. raised its holdings in Henry Schein by 23.2% in the 1st quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after purchasing an additional 201 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.